Product logins

Find logins to all Clarivate products below.


Axial Spondyloarthritis – Landscape & Forecast – Disease Landscape & Forecast (Major Markets)

The axial spondyloarthritis (AxSpA) treatment landscape consists of biologics from two established classes: TNF-α inhibitors (Amgen/Pfizer’s Enbrel, AbbVie’s Humira, Johnson & Johnson Innovative Medicine’s Remicade and Simponi/Simponi Aria, and UCB’s Cimzia) and IL-17 inhibitors (Novartis’s Cosentyx, Eli Lilly’s Taltz, and UCB’s Bimzelx). TNF-α inhibitors are widely used after inadequate response to NSAIDs, although their role has shifted with the availability of cost-effective biosimilars and increasing use of IL-17 inhibitors. Since UCB’s Cimzia became the first FDA-approved therapy for non-radiographic AxSpA (nr-AxSpA) in 2019, treatment options have expanded to include IL-17 inhibitors and oral JAK inhibitors such as AbbVie’s Rinvoq (and Pfizer’s Xeljanz for AS).

Questions answered:

  • How large is the treatable AxSpA population, and how will diagnosis / drug-treatment rates change over time?
  • What are experts’ insights on current treatment options for AS and nr-AxSpA? What clinical needs remain unfulfilled?
  • What pipeline products are the most promising, and what key therapies are in early-phase development?
  • What are experts’ opinions of the use of Bimzelx, Xeljanz and Rinvoq for AS? What sales / uptake could non-TNF therapies secure in AxSpA?
  • What are the drivers of and constraints in the AxSpA therapy market, and how will the market evolve over the forecast period?

Content highlights:

Geographies: United States, EU5, Japan

Primary research: Country-specific interviews with thought-leading rheumatologists; supported by survey data collected for this and other Clarivate research.

Epidemiology: Diagnosed prevalent cases of AxSpA by country; AS and nr-AxSpA subpopulations.

Forecast: 10-year, annualized, drug-level sales and patient share of key AxSpA therapies through 2035, segmented by brands / generics and epidemiological subpopulations

Drug treatments: Coverage of key current and late-phase emerging therapies

Product description: Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

  • Optimize your long-term disease and development strategy.
  • Quantify market potential for your pipeline assets and those of your competitors.
  • Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
  • Gauge the commercial outlook and impact of key market events.

Table of contents


Related Market Assessment Reports

Report
Non-Small-Cell Lung Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
The multibillion-dollar NSCLC therapy market is highly dynamic, with more than 40 targeted drugs approved, but still a high unmet need. Immune checkpoint inhibitors such as Keytruda (Merck & Co.)…
Report
Gastroesophageal Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
The immune checkpoint inhibitors Opdivo (Bristol Myers Squibb / Ono Pharmaceutical) and Keytruda (Merck & Co.) have revolutionized the treatment of gastroesophageal cancer, driving substantial…
Report
Bladder Cancer and Upper Tract Urothelial Carcinoma – Landscape & Forecast – Disease Landscape & Forecast (G7)
The treatment landscape for bladder cancer and upper tract urothelial carcinoma (UTUC) continues to evolve rapidly, driven by the expanding use of immune checkpoint inhibitors, antibody-drug…
Report
Scleroderma (Systemic Sclerosis) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Scleroderma (Systemic Sclerosis) (US)
Scleroderma (systemic sclerosis, SSc) is a rare, progressive autoimmune disease marked by skin fibrosis, systemic inflammation, and vasculopathy, leading to Raynaud’s phenomenon and painful…
Report
Bladder Cancer and Upper Tract Urothelial Carcinoma – Geographic Focus: China – Bladder Cancer and Upper Tract Urothelial Carcinoma – China In-Depth – China
China’s bladder cancer market is entering a period of accelerated expansion, as novel branded therapies reshape systemic management. A major growth driver is the expanding role of immune…